The Trump administration is planning an experiment to cover weight loss drugs under Medicare and Medicaid, potentially ...

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

The Center for Medicare and Medicaid Innovation may introduce a five-year pilot model to expand access to weight loss drugs, ...

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

The Trump administration is considering a proposal to allow Medicare and Medicaid to cover expensive weight-loss drugs. GLP-1 ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Medicare is barred under a 2003 law from paying for weight-loss medications like Wegovy. Lawmakers on Thursday reintroduced a bill that would expand Medicare coverage to the drugs.

President Joe Biden's proposal to have GLP-1 weight-loss drugs such as Wegovy, Ozempic, Zepbound and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity ...

New weight-loss drugs are out of reach for millions of older Americans because Medicare won’t pay Debra Tyler’s daughter takes her new medication at home in Killingworth, Conn.